These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 29730950)

  • 41. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
    Meng MV; Gschwend JE; Shore N; Grossfeld GD; Mostafid H; Black PC
    J Urol; 2019 Dec; 202(6):1111-1119. PubMed ID: 31042108
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer.
    Melgarejo-Segura MT; Morales-Martínez A; Yáñez-Castillo Y; Arrabal-Polo MÁ; Gómez-Lechuga P; Pareja-Vílchez M; Jiménez-Moleón JJ; Martín MA
    Urol Oncol; 2023 Apr; 41(4):166-176. PubMed ID: 36328923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
    Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA;
    Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin immunotherapy.
    Ajili F; Manai M; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2012 Oct; 36(5):320-4. PubMed ID: 23025650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
    Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
    Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mitomycin C for the treatment of bladder cancer.
    Volpe A; Racioppi M; D'Agostino D; Cappa E; Filianoti A; Bassi PF
    Minerva Urol Nefrol; 2010 Jun; 62(2):133-44. PubMed ID: 20562793
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.
    Packiam VT; Richards J; Schmautz M; Heidenreich A; Boorjian SA
    Curr Opin Urol; 2021 May; 31(3):178-187. PubMed ID: 33742981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Valrubicin in refractory non-muscle invasive bladder cancer.
    Sharma P; Zargar-Shoshtari K; Sexton WJ
    Expert Rev Anticancer Ther; 2015; 15(12):1379-87. PubMed ID: 26569509
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salvage therapeutic strategies for bacillus Calmette-Guerin failure.
    Hassler MR; Shariat SF; Soria F
    Curr Opin Urol; 2019 May; 29(3):239-246. PubMed ID: 30762670
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune therapies in non-muscle invasive bladder cancer.
    Ho PL; Williams SB; Kamat AM
    Curr Treat Options Oncol; 2015 Feb; 16(2):5. PubMed ID: 25757877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer.
    Tabayoyong WB; Kamat AM; O'Donnell MA; McKiernan JM; Ray-Zack MD; Palou J; Brausi M; Black PC; Williams SB
    Eur Urol Focus; 2018 Jul; 4(4):512-521. PubMed ID: 30190111
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
    Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
    J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer.
    Steinberg RL; Thomas LJ; O'Donnell MA
    Eur Urol Focus; 2018 Jul; 4(4):503-505. PubMed ID: 30017900
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage.
    Veeratterapillay R; Heer R; Johnson MI; Persad R; Bach C
    Curr Urol Rep; 2016 Sep; 17(9):68. PubMed ID: 27492610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging treatment options for bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
    Kokorovic A; Ory J; Saad F
    Curr Opin Support Palliat Care; 2022 Mar; 16(1):48-53. PubMed ID: 35086977
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
    Hannouneh ZA; Hijazi A; Alsaleem AA; Hami S; Kheyrbek N; Tanous F; Khaddour K; Abbas A; Alshehabi Z
    Cancer Med; 2023 Dec; 12(24):21944-21968. PubMed ID: 38037752
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Salvage Therapies for Non-muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Guérin? Predictors and Nomograms.
    Faba ÓR; Pisano F; Krajewski W; Breda A; Palou J
    Urol Clin North Am; 2020 Feb; 47(1):5-13. PubMed ID: 31757300
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravesical electro-osmotic administration of mitomycin C.
    Di Stasi SM; Verri C; Celestino F; De Carlo F; Pagliarulo V
    Urologia; 2016 Oct; 83(Suppl 2):18-23. PubMed ID: 27716887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.